Evogene Ltd. (EVGN)

Evogene Statistics

Total Valuation

Evogene has a market cap or net worth of $11.79 million. The enterprise value is $8.55 million.

Market Cap	11.79M
Enterprise Value	8.55M

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024, before market open.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Evogene has 5.10 million shares outstanding. The number of shares has increased by 21.04% in one year.

Shares Outstanding	5.10M
Shares Change (YoY)	+21.04%
Shares Change (QoQ)	+0.57%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	4.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	0.94
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.58, with a Debt / Equity ratio of 0.04.

Current Ratio	1.58
Quick Ratio	1.32
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -82.37% and return on invested capital (ROIC) is -50.33%.

Return on Equity (ROE)	-82.37%
Return on Assets (ROA)	-28.46%
Return on Capital (ROIC)	-50.33%
Revenue Per Employee	$66,542
Profits Per Employee	-$139,908
Employee Count	142
Asset Turnover	0.20
Inventory Turnover	3.37

Taxes

Income Tax	-8,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.01% in the last 52 weeks. The beta is 1.02, so Evogene's price volatility has been similar to the market average.

Beta (5Y)	1.02
52-Week Price Change	-64.01%
50-Day Moving Average	2.76
200-Day Moving Average	5.86
Relative Strength Index (RSI)	34.40
Average Volume (20 Days)	748,450

Short Selling Information

Short Interest	26,791
Short Previous Month	14,621
Short % of Shares Out	0.50%
Short % of Float	n/a
Short Ratio (days to cover)	1.00

Income Statement

In the last 12 months, Evogene had revenue of $9.45 million and -$19.87 million in losses. Loss per share was -$3.95.

Revenue	9.45M
Gross Profit	7.69M
Operating Income	-21.48M
Pretax Income	-21.46M
Net Income	-19.87M
EBITDA	-19.67M
EBIT	-21.48M
Loss Per Share	-$3.95

Balance Sheet

The company has $20.91 million in cash and $810,000 in debt, giving a net cash position of $20.10 million or $3.94 per share.

Cash & Cash Equivalents	20.91M
Total Debt	810,000
Net Cash	20.10M
Net Cash Per Share	$3.94
Equity (Book Value)	19.94M
Book Value Per Share	0.60
Working Capital	9.49M

Cash Flow

In the last 12 months, operating cash flow was -$19.81 million and capital expenditures -$474,000, giving a free cash flow of -$20.28 million.

Operating Cash Flow	-19.81M
Capital Expenditures	-474,000
Free Cash Flow	-20.28M
FCF Per Share	-$3.98

Margins

Gross margin is 81.42%, with operating and profit margins of -227.27% and -210.26%.

Gross Margin	81.42%
Operating Margin	-227.27%
Pretax Margin	-222.59%
Profit Margin	-210.26%
EBITDA Margin	-208.19%
EBIT Margin	-227.27%
FCF Margin	-217.65%

Dividends & Yields

Evogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.04%
Shareholder Yield	-21.04%
Earnings Yield	-168.57%
FCF Yield	-172.08%

Analyst Forecast

The average price target for Evogene is $12.00, which is 474.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.00
Price Target Difference	474.16%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jul 25, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

Evogene has an Altman Z-Score of -9.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-9.26
Piotroski F-Score	3